{"product_id":"gsk-swot-analysis","title":"(GSK) GSK plc SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis GSK plc SWOT Analysis gives a concise, ready-made breakdown of the company’s strengths, weaknesses, opportunities, and threats to support research, strategy, or investment work. This page includes a real preview of the analysis so you can review format and substance before buying — purchase the full version to download the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1715-founded global pharma with 2 operating divisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFounded in 1715, GSK plc brings more than 300 years of operating history and a wide footprint across the UK, the US, and global markets. Its Commercial Operations and Total R\u0026amp;D split gives it both sales reach and deep drug-development capability. That scale helped GSK generate £31.4 billion in 2024 sales and support vaccines and medicines execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong vaccine portfolio across 5 major disease areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK’s vaccines business spans shingles, meningitis, RSV, flu, and polio, so it reaches both routine shots and high-need public health use. In 2024, GSK reported vaccines sales of about £9.1 billion, showing how large and stable this franchise is. Demand also rises with older populations and prevention-led care spending, which supports repeat use across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad medicines base in HIV, oncology, respiratory and immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc’s broad base spans HIV, oncology, respiratory and immunology, so it is not tied to one drug or one market. In FY2025, that mix supported a sales base above £30 billion, with inhaled asthma\/COPD therapies, antibiotics and specialty medicines adding depth. This spread lowers single-segment risk and helps smooth demand shifts across cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-led innovation model with multiple external alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK plc’s partnership-led model is a clear strength because it widens access to mRNA, oligonucleotide, fibrosis, osteoarthritis, Parkinson’s, and new discovery tools through CureVac, Wave Life Sciences, Elsie Biotechnologies, Relation, and Flagship Pioneering. It can speed R\u0026amp;D and spread scientific risk across multiple partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroadens platform access\u003c\/li\u003e\n\u003cli\u003eShares R\u0026amp;D risk\u003c\/li\u003e\n\u003cli\u003eSpeeds target discovery\u003c\/li\u003e\n\u003cli\u003eSupports pipeline optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished scale in preventive and treatment markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK’s scale across vaccines, specialty medicines, and general medicines gives it reach in both prevention and treatment, not just one side of care. In FY2024, GSK posted £31.4 billion in sales, with vaccines at £9.0 billion, so it can serve hospitals, clinics, and pharmacies from one platform. That mix also cuts concentration risk versus narrow biotech peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad care mix supports more stable demand\u003c\/li\u003e\n\u003cli\u003eVaccines and medicines widen customer access\u003c\/li\u003e\n\u003cli\u003e£31.4bn sales show real operating scale\u003c\/li\u003e\n\u003cli\u003eLess exposed than single-therapy players\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s Broad Portfolio Powers Steady Growth and Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s strength is its broad mix of vaccines, specialty medicines, and general medicines, which helps balance demand across care settings. In FY2025, sales stayed above £30 billion, showing real scale and resilience. Its vaccines franchise also remains a key pillar, with 2024 sales of about £9.1 billion. That spread lowers concentration risk and supports steady cash generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eFY2025\/2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003eAbove £30bn in FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines sales\u003c\/td\u003e\n\u003ctd\u003eAbout £9.1bn in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing GSK plc’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick GSK plc SWOT snapshot to cut through strategy pain points and speed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources backing market, pricing, and competitive assumptions to speed verification and strengthen investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh dependence on R\u0026amp;D success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc’s weak spot is its heavy reliance on R\u0026amp;D success: in 2024, the Company spent about £6.7 billion on R\u0026amp;D, roughly 21% of sales, yet drug development can take 10+ years and many programs fail late. If a key asset misses approval, revenue can slip and returns on research spend fall fast. That makes growth tied to a small number of approved launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex portfolio across vaccines and medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc runs three reporting segments: Vaccines, Specialty Medicines, and General Medicines, which makes the portfolio hard to manage. Each area has different regulatory, manufacturing, and launch rules, so execution risk rises. With such breadth, prioritizing capital and management focus is harder, and slower products can drag on returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation partly reliant on external partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc still leans on external partners to access platforms and tech, so it can move faster, but it also shares more of the upside. That weakens control over timelines, economics, and IP. When a large part of innovation is partner-led, execution risk rises if a deal slips or terms change.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExposure to pricing and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK plc faces clear pricing and reimbursement pressure because public payers and private insurers keep pushing down drug and vaccine net prices, especially in mature markets. In FY2024, GSK reported £31.4 billion in sales, so even small rebates or formulary cuts can dent profit fast. Demand can stay strong, but margins still get squeezed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice cuts hit large revenue base.\u003c\/li\u003e\n\u003cli\u003ePayer rules can cap margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLarge exposure to regulated manufacturing and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK plc’s weakness is its heavy exposure to tightly regulated vaccine and medicine manufacturing, where even small quality or inspection failures can stop production and delay supply. That raises fixed compliance costs because the company must meet GMP, batch-release, and cold-chain rules across multiple sites and products. Any disruption can hit sales fast, since these are high-value, time-sensitive healthcare products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuality issues can halt batches.\u003c\/li\u003e\n\u003cli\u003eInspections can disrupt supply.\u003c\/li\u003e\n\u003cli\u003eCompliance costs stay structurally high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s R\u0026amp;D-heavy model faces pricing pressure and compliance risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s main weakness is concentration risk: FY2024 R\u0026amp;D spend was about £6.7 billion, or 21% of sales, yet late-stage failures can still wipe out years of work. Pricing pressure also weighs on returns, with FY2024 sales of £31.4 billion exposed to payer cuts. Heavy regulation and quality controls keep costs high and can halt supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eFY2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D intensity\u003c\/td\u003e\n\u003ctd\u003e£6.7bn, 21% of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales base at risk\u003c\/td\u003e\n\u003ctd\u003e£31.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance burden\u003c\/td\u003e\n\u003ctd\u003eHigh GMP and cold-chain costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGSK plc Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete GSK plc SWOT analysis document—no surprises, just professional quality you’ll receive after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emRNA vaccine expansion with CureVac\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc’s collaboration with CureVac opens a direct route into mRNA influenza vaccines, a platform that can be redesigned in weeks rather than months. The move could widen GSK plc’s pipeline beyond flu into combo shots and other next-gen immunization targets. If the program works, it should strengthen GSK plc’s grip in a market where rapid strain matching matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOligonucleotide platforms with Wave Life Sciences and Elsie Biotechnologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWave Life Sciences and Elsie Biotechnologies give GSK access to nucleic-acid tools that can expand into hard-to-treat diseases, where oligonucleotide drugs are one of the fastest-growing parts of R\u0026amp;D. One platform can also spin out multiple follow-on assets, so GSK can build depth from a single technology base instead of funding each program from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFibrotic disease and osteoarthritis programs with Relation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFibrotic disease affects more than 100 million people worldwide, and osteoarthritis impacts about 595 million, so both areas offer huge unmet need. GSKs dual collaborations with Relation widen its specialty pipeline beyond vaccines and HIV, adding optionality in higher-growth fields. Positive phase 1 and phase 2 readouts could create long-term value if they de-risk larger studies and future royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eParkinsons alliance and novel medicine discovery with Flagship Pioneering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eParkinson’s affects more than 10 million people worldwide, yet there is still no approved disease-modifying therapy, so it remains a big neuroscience gap. GSK plc’s alliance with Flagship Pioneering can tap frontier biology and faster target discovery, which may lift R\u0026amp;D into higher-value, platform-led innovation beyond legacy drug classes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10M+ patients worldwide\u003c\/li\u003e\n\u003cli\u003eNo disease-modifying cure\u003c\/li\u003e\n\u003cli\u003eAccess to new targets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis could widen GSK plc’s shot at first-in-class assets in a market with clear unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrowing demand for RSV, influenza, and adult immunization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDemand for adult vaccines is rising as people age: the UN says the global 65+ population will reach about 1.6 billion by 2050. GSK already has RSV and influenza assets, so better uptake can turn seasonal prevention into steadier vaccine revenue; its Vaccines sales were £7.8 billion in 2024, showing the scale of this base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder adults need more prevention\u003c\/li\u003e\n\u003cli\u003eRSV and flu fit GSK's portfolio\u003c\/li\u003e\n\u003cli\u003eHigher uptake means repeat sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK's vaccine pipeline could unlock faster, recurring growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s biggest opportunities sit in vaccines and platform deals that can refresh the pipeline fast, especially mRNA flu and adult RSV shots. With Vaccines revenue at £7.8 billion in 2024, even modest uptake gains can lift recurring sales.\u003c\/p\u003e\n\u003cp\u003eIts bets with CureVac, Wave Life Sciences, Elsie Biotechnologies, Relation, and Flagship Pioneering widen access to nucleic acids, fibrosis, osteoarthritis, and neuroscience. That gives GSK more shots at first-in-class assets in large unmet-need markets.\u003c\/p\u003e\n\u003cp\u003eAgeing populations should keep demand rising: the UN expects about 1.6 billion people aged 65+ by 2050, which supports more flu and RSV demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult vaccines\u003c\/td\u003e\n\u003ctd\u003e£7.8bn Vaccines sales in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgeing demand\u003c\/td\u003e\n\u003ctd\u003e1.6bn people aged 65+ by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense competition in vaccines and specialty medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK faces heavy competition from Pfizer, Merck, Sanofi, and AstraZeneca in vaccines and specialty medicines. In 2025, GSK reported about £31.4 billion in revenue, but rivals can still win share with faster approvals, bigger sales teams, or lower prices. That can squeeze GSK’s margins, especially in vaccines where a few products drive a large share of sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent loss and lifecycle pressure in medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc faces real patent-loss risk as medicines age and generics or biosimilars enter, which can quickly cut sales. In 2024, GSK reported £31.4 billion of turnover, but that base still depends on a few big brands that will need replacement over time.\u003c\/p\u003e\n\u003cp\u003eThis lifecycle pressure means GSK must keep launching new drugs to offset erosion from older products, or revenue can stall. If a high-value medicine loses exclusivity, price and volume can drop fast, so pipeline depth matters more each year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk across multiple pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK plc faces binary trial risk: drug and vaccine assets can fail in Phase 1, Phase 2, or Phase 3, and one late-stage miss can erase expected future sales. In 2024, GSK reported £31.4 billion in sales, so even a single major pipeline setback can hit revenue, margin, and valuation fast. Pipeline swings stay a structural biotech threat, and the company still depends on a few high-value programs to offset failures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and safety scrutiny in 2026 markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK plc faces tight 2026 scrutiny because vaccines and medicines must clear regulators like the FDA and EMA, and any safety signal can force label changes, pauses, or slower launches. Compliance failures can raise costs fast and hurt trust; GSK’s 2025 total sales were £31.4bn, so even a delay in a major product can hit a large base. One adverse review can ripple across approvals and revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSafety signals can delay launches\u003c\/li\u003e\n\u003cli\u003eLabel changes can cut sales\u003c\/li\u003e\n\u003cli\u003eCompliance lapses raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMacro shocks to demand, supply, and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflation, shipping delays, and geopolitics can lift GSK plc manufacturing and distribution costs, while also slowing deliveries to key markets. When public health systems face tighter budgets, vaccine and specialty drug uptake can soften, and launch timing can slip. This matters most when demand is price-sensitive and inventory needs are long. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher input and freight costs\u003c\/li\u003e\n\u003cli\u003eDelays in plant output and shipping\u003c\/li\u003e\n\u003cli\u003eTighter healthcare spending\u003c\/li\u003e\n\u003cli\u003eSlower uptake and margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s Key Risks: Patents, Trial Setbacks, and Rival Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s biggest threats are patent loss, trial failure, and tough rivals. In 2025, GSK posted £31.4bn in sales, so any late-stage miss or loss of exclusivity on a key brand can hit revenue fast. FDA or EMA delays, safety signals, and rising input costs can also squeeze margins and slow launches.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234455462153,"sku":"gsk-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gsk-swot-analysis.webp?v=1785720433","url":"https:\/\/dcfanalyst.com\/products\/gsk-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}